Belzupacap sarotalocan is a recombinant protein commercialized by Aura Biosciences, with a leading Phase II program in Uveal Melanoma. According to Globaldata, it is involved in 6 clinical trials, of which 1 was completed, 3 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Belzupacap sarotalocan’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Belzupacap sarotalocan is expected to reach an annual total of $28 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Belzupacap sarotalocan Overview
AU-011 is under development for the treatment of ocular melanoma (melanomas of the iris and the ciliary body), uveal and choroidal melanoma. It is administered as an intravitreal, suprachoroidal, intratumoral and intramural route. The therapeutic candidate is developed based on Nanosmart technology. The drug candidate is a VDC (virus like drug conjugate).
Aura Biosciences Overview
Aura Biosciences is working on a novel class of oncology targeted therapeutics that will provide considerable therapeutic benefit to a variety of cancer indications with a high unmet need. The company is headquartered in United States.
The operating loss of the company was US$35.3 million in FY2021, compared to an operating loss of US$22.2 million in FY2020. The net loss of the company was US$35.3 million in FY2021, compared to a net loss of US$22.2 million in FY2020.
For a complete picture of Belzupacap sarotalocan’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.